Zilovertamab Vedotin

Ewing Sarcoma

Merck Sharp & Dohme LLCantibody_drug_conjugatePhase 1/2Active

CC

45/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 33/ 100
Competitive Position: 81/ 100

Competitive context

56 Active assets in the Ewing Sarcoma cohort.

Asset / Sponsor	Phase	Rating
Irinotecan Milton S. Hershey Medical Center	Phase 3	BB
Nivolumab Children's National Research Institute	Phase 2	B
Cyclophosphamide Essen Biotech	Phase 2	B
Hycamtin Pfizer	Phase 2	B
Inno-206 Children's National Research Institute	Phase 2	B

View all 50 →

Same molecule, other indications

Zilovertamab Vedotin is also rated in:

diffuse large B-cell lymphomaDormant

BB

Indicative ·

64 / 100

Richter transformationDormant

B

Indicative ·

60 / 100

relapsed/refractory diffuse large B-cell lymphomaDormant

B

Indicative ·

57 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.